에 대한 최신 뉴스 WAVE Life Sciences (NASDAQ:WVE) 주식

WAVE Life Sciences

WAVE Life Sciences Ltd is unlocking the broad potential of RNA medicines also known as oligonucleotides, it targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISMTM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, splicing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.

Mid Cap

News

Movers

Trading Ideas

$BTC

AMZN

CLSK

IONQ

LBPH

OKLO

WOLF

이들 7개 중형주는 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요?

오클로, 클린스파크 및 울프스피드는 지난주 최고 성과를 보여준 7개 중형주 중 일부 (10월 14일-18일)

Wave Life Sciences Ltd. - Ordinary Shares

WAVE Life Sciences Ltd

These seven mid-cap stocks were the best performers in the last week. Are they in your portfolio?
<ol>
<li>Oklo Inc.&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OKLO#NYSE">OKLO</a>) stock gained 99.23% last week. Nuclear-linked stocks gained after Amazon Inc.&#8217;s (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) AWS <a href="https://www.benzinga.com//node/41358363" target="_blank" rel="noreferrer noopener">announced plans to invest</a> over $500 million in nuclear power.</li>
<li>Wave Life Sciences Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WVE#NASDAQ">WVE</a>) shares jumped 67.35% after the company achieved its first-ever therapeutic RNA editing in humans from its RestorAATion-2 trial of WVE-006 for <a href="https://www.benzinga.com//node/41359843" target="_blank" rel="noreferrer noopener">Alpha-1 antitrypsin deficiency</a>. Several analysts raised the price <a href="https://www.benzinga.com/quote/wve/analyst-ratings" target="_blank" rel="noreferrer noopener">target on the stock</a>.</li>
<li>Longboard Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LBPH#NASDAQ">LBPH</a>) gained 52.21% after the company announced it would be acquired by Lundbeck <a href="https://www.benzinga.com//node/41313129" target="_blank" rel="noreferrer noopener">for $60 per share in cash</a>.</li>
<li>Wolfspeed, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WOLF#NYSE">WOLF</a>) shares rocketed 42.44% after signing a non-binding preliminary memorandum of terms for up to $750 million in proposed direct funding under <a href="https://www.benzinga.com//node/41339603" target="_blank" rel="noreferrer noopener">the CHIPS and Science Act</a>.</li>
<li>CleanSpark, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLSK#NASDAQ">CLSK</a>) stock upped 34.10% last week after Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) <a href="https://www.benzinga.com//node/41386011" target="_blank" rel="noreferrer noopener">rose above $67,000</a>.</li>
<li>Telephone and Data Systems, Inc. (NYS: TDS) soared 26.03% after the company announced its subsidiary, United State Cellular Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USM#NYSE">USM</a>), <a href="https://www.benzinga.com//node/41403665" target="_blank" rel="noreferrer noopener">selling select spectrum licenses</a> in the AWS and PCS bands.</li>
<li>IonQ, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IONQ#NYSE">IONQ</a>) shares increased 15.31%. The company will report third-quarter <a href="https://www.benzinga.com/earnings" target="_blank" rel="noreferrer noopener">financial results on November 6</a>.</li>
</ol>
Also Read:
<ul>
<li><a href="https://www.benzinga.com//node/41418999" target="_blank" rel="noreferrer noopener">NIO, ASML, And CVS Health Are Among Top 10 Large Cap Losers Last Week (Oct 14-18): Are The Others In Your Portfolio?</a></li>
<li><a href="https://www.benzinga.com/news/large-cap/24/10/41418879/coinbase-united-airlines-and-sofi-tech-are-among-top-11-large-cap-gainers-last-week-oct-14-18-are-" target="_blank" rel="noreferrer noopener">Coinbase, United Airlines And Sofi Tech Are Among Top 11 Large Cap Gainers Last Week (Oct 14-18): Are The Others In Your Portfolio?</a></li>
</ul>
Photo Courtesy of Oklo

Oklo, CleanSpark And Wolfspeed Are Among Top 7 Mid Cap Gainers Last Week (Oct 14-18): Are The Others In Your Portfolio?

HC Wainwright &amp; Co. analyst Andrew Fein reiterates WAVE Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WVE#NASDAQ">WVE</a>) with a Buy and maintains $22 price target.

Price Target

Reiteration

Analyst Ratings

HC Wainwright & Co. Reiterates Buy on WAVE Life Sciences, Maintains $22 Price Target

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/587639df5064ed0001400135/david-manthey">Baird analyst David Manthey</a> upgraded the rating for W.W. Grainger, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GWW#NYSE">GWW</a>) from Neutral to Outperform and raised the price target from $975 to $1,230. Grainger shares closed at $1,085.57 on Tuesday. <a href="https://www.benzinga.com/quote/GWW/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>B of A Securities analyst David Begleiter upgraded Westlake Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WLK#NYSE">WLK</a>) from Underperform to Neutral and boosted the price target from $151 to $159. Westlake shares closed at $141.80 on Tuesday. <a href="https://www.benzinga.com/quote/WLK/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Citigroup analyst Atif Malik upgraded the rating for Cisco Systems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSCO#NASDAQ">CSCO</a>) from Neutral to Buy and increased the price target from $52 to $62. Cisco shares closed at $54.08 on Tuesday. <a href="https://www.benzinga.com/quote/CSCO/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Cleveland Research upgraded the rating for SAP SE (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SAP#NYSE">SAP</a>) from Neutral to Buy. SAP shares closed at $229.52 on Tuesday. <a href="https://www.benzinga.com/quote/SAP/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Raymond James analyst Steven Seedhouse upgraded Wave Life Sciences Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WVE#NASDAQ">WVE</a>) from Outperform to Strong Buy and increased the price target from $13 to $22. WAVE Life Sciences shares closed at $8.56 on Tuesday. <a href="https://www.benzinga.com/quote/WVE/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying CSCO stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="517" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/16144213/image-130-1024x517.png" alt="" class="wp-image-599072" style="width:632px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/16144213/image-130-1024x517.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/16144213/image-130-300x152.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/16144213/image-130-768x388.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/16144213/image-130.png 1297w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read More:<a href="https://www.benzinga.com/news/24/10/41358280/united-airlines-posts-upbeat-earnings-joins-morgan-stanley-u-s-bancorp-and-other-big-stocks-moving-h"> </a>
<ul>
<li><a href="https://www.benzinga.com/news/24/10/41358280/united-airlines-posts-upbeat-earnings-joins-morgan-stanley-u-s-bancorp-and-other-big-stocks-moving-h">United Airlines Posts Upbeat Earnings, Joins Morgan Stanley, U.S. Bancorp And Other Big Stocks Moving Higher On Wednesday</a></li>
</ul>

Upgrades

Markets

CSCO

This Cisco Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday

Raymond James analyst Steven Seedhouse upgrades WAVE Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WVE#NASDAQ">WVE</a>) from Outperform to Strong Buy and raises the price target from $13 to $22.

Raymond James Upgrades WAVE Life Sciences to Strong Buy, Raises Price Target to $22

Wells Fargo analyst Tiago Fauth maintains WAVE Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WVE#NASDAQ">WVE</a>) with a Overweight and raises the price target from $11 to $22.

Wells Fargo Maintains Overweight on WAVE Life Sciences, Raises Price Target to $22

Leerink Partners analyst Mani Foroohar maintains WAVE Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WVE#NASDAQ">WVE</a>) with a Outperform and raises the price target from $20 to $22.

Leerink Partners Maintains Outperform on WAVE Life Sciences, Raises Price Target to $22

Whales with a lot of money to spend have taken a noticeably bullish stance on WAVE Life Sciences.
Looking at options history for WAVE Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WVE#NASDAQ">WVE</a>) we detected 13 trades.
If we consider the specifics of each trade, it is accurate to state that 53% of the investors opened trades with bullish expectations and 46% with bearish.
From the overall spotted trades, 3 are puts, for a total amount of $251,490 and 10, calls, for a total amount of $481,968.
<h3>Expected Price Movements</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $7.5 to $15.0 for WAVE Life Sciences during the past quarter. 
<h3>Volume &amp; Open Interest Development</h3>
In terms of liquidity and interest, the mean open interest for WAVE Life Sciences options trades today is 608.71 with a total volume of 10,303.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for WAVE Life Sciences's big money trades within a strike price range of $7.5 to $15.0 over the last 30 days.
<h3>WAVE Life Sciences Option Volume And Open Interest Over Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1729097158_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>WVE</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$2.15</td>
<td>$1.7</td>
<td>$1.7</td>
<td>$12.50</td>
<td>$170.0K</td>
<td>1</td>
<td>1.0K</td>
</tr>
<tr>
<td>WVE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>11/15/24</td>
<td>$2.5</td>
<td>$1.95</td>
<td>$2.0</td>
<td>$15.00</td>
<td>$84.8K</td>
<td>3</td>
<td>1.9K</td>
</tr>
<tr>
<td>WVE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$7.9</td>
<td>$7.5</td>
<td>$7.7</td>
<td>$7.50</td>
<td>$77.0K</td>
<td>510</td>
<td>111</td>
</tr>
<tr>
<td>WVE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$7.7</td>
<td>$7.4</td>
<td>$7.5</td>
<td>$7.50</td>
<td>$75.0K</td>
<td>510</td>
<td>212</td>
</tr>
<tr>
<td>WVE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$5.9</td>
<td>$5.6</td>
<td>$5.67</td>
<td>$7.50</td>
<td>$56.9K</td>
<td>1.3K</td>
<td>114</td>
</tr>
</tbody>
</table>

<h3>About WAVE Life Sciences</h3>
WAVE Life Sciences Ltd is unlocking the broad potential of RNA medicines also known as oligonucleotides, it targeting ribonucleic acid (RNA), to transform human health. RNA medicines platform, PRISMTM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, splicing, antisense silencing, and RNA interference, providing capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its programs are for rare and prevalent diseases, including alpha-1 antitrypsin deficiency, obesity, Duchenne muscular dystrophy, and Huntington's disease.
In light of the recent options history for WAVE Life Sciences, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>WAVE Life Sciences's Current Market Status</h3>
<ul>
<li>Currently trading with a volume of 13,020,486, the WVE's price is up by 74.92%, now at $14.97. </li>
<li>RSI readings suggest the stock is currently may be overbought.</li>
<li>Anticipated earnings release is in 22 days.</li>
</ul>
<h3>Professional Analyst Ratings for WAVE Life Sciences</h3>
5 market experts have recently issued ratings for this stock, with a consensus target price of $14.4.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from RBC Capital keeps a Sector Perform rating on WAVE Life Sciences with a target price of $7. 
&#x2A; An analyst from B. Riley Securities has revised its rating downward to Buy, adjusting the price target to $11. 
&#x2A; Maintaining their stance, an analyst from B. Riley Securities continues to hold a Buy rating for WAVE Life Sciences, targeting a price of $19. 
&#x2A; An analyst from JP Morgan has revised its rating downward to Overweight, adjusting the price target to $13. 
&#x2A; An analyst from HC Wainwright &amp; Co. has decided to maintain their Buy rating on WAVE Life Sciences, which currently sits at a price target of $22. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for WAVE Life Sciences with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Options

Looking At WAVE Life Sciences's Recent Unusual Options Activity

<h3>Gainers</h3>
<ul>
<li>180 Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATNF#NASDAQ">ATNF</a>) stock rose 503.9% to $9.18 during Wednesday's regular session. The company's market cap stands at $9.4 million. </li>
<li>Korro Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRRO#NASDAQ">KRRO</a>) shares moved upwards by 124.86% to $89.41. The company's market cap stands at $831.3 million. </li>
<li>Universe Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPC#NASDAQ">UPC</a>) shares increased by 111.79% to $0.93. The company's market cap stands at $21.9 million. </li>
<li>Quoin Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QNRX#NASDAQ">QNRX</a>) shares moved upwards by 84.92% to $0.93. The market value of their outstanding shares is at $3.7 million. </li>
<li>WAVE Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WVE#NASDAQ">WVE</a>) stock moved upwards by 75.23% to $15.0. The company's market cap stands at $2.2 billion. </li>
<li>Biodexa Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BDRX#NASDAQ">BDRX</a>) shares increased by 54.07% to $7.72. The market value of their outstanding shares is at $112.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Novavax (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) stock declined by 17.4% to $10.41 during Wednesday's regular session. The market value of their outstanding shares is at $1.6 billion. </li>
<li>Tevogen Bio Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TVGN#NASDAQ">TVGN</a>) stock fell 15.27% to $1.16. The market value of their outstanding shares is at $198.1 million. </li>
<li>LogicMark (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGMK#NASDAQ">LGMK</a>) shares decreased by 11.01% to $0.08. </li>
<li>Vicarious Surgical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBOT#NYSE">RBOT</a>) shares fell 9.95% to $8.01. The company's market cap stands at $47.2 million. </li>
<li>Klotho Neurosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLTO#NASDAQ">KLTO</a>) stock decreased by 8.61% to $0.47. The market value of their outstanding shares is at $9.9 million. </li>
<li>Genprex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GNPX#NASDAQ">GNPX</a>) stock fell 8.58% to $0.31. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ATNF

BDRX

GNPX

KLTO

KRRO

LGMK

NVAX

QNRX

RBOT

TVGN

12 Health Care Stocks Moving In Wednesday's Intraday Session

WIIM

Wave Life Sciences shares are trading higher after the company announced it achieved its first-ever therapeutic RNA editing in humans from its RestorAATion-2 trial of WVE-006 for Alpha-1 antitrypsin deficiency.

Wave Life Sciences Ltd.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WVE#NASDAQ">WVE</a>) stock is trading higher on Wednesday after the company revealed proof-of-mechanism data from the ongoing Phase 1b/2a RestorAATion-2 study of WVE-006 in alpha-1 antitrypsin deficiency (AATD), an inherited genetic disorder that causes low levels of a protein (AAT) that <a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/g41355354/wave-life-sciences-announces-first-ever-therapeutic-rna-editing-in-humans-achieved-in-restoraation" rel="noreferrer noopener">protects the lungs</a>.
The condition can cause lung and liver damage.
WVE-006 is designed to address AATD-related lung disease, liver disease, or both.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/41007614/wave-life-sciences-stock-surges-on-promising-interim-data-from-mid-stage-study-of-muscular-disord" rel="noreferrer noopener">Wave Life Sciences Stock Surges On Promising Interim Data From Mid-Stage Study Of Muscular Disorder Drug</a>.
The company adds that today&#8217;s proof-of-mechanism data are the first-ever clinical demonstration of RNA editing in humans.
These data are from the first single-dose cohort (200 mg) in RestorAATion-2 and include the first two patients with &#8220;ZZ&#8221; AATD (Pi&#x2A;ZZ AATD) to reach day 57.
Individuals with Pi&#x2A;ZZ AATD do not naturally produce wild-type alpha-1 antitrypsin (M-AAT) protein; therefore, the presence of M-AAT protein is confirmation of successful editing of mutant Z-AAT mRNA.
Additionally, restoring 50% M-AAT would be consistent with the heterozygous &#8220;MZ&#8221; genotype with low risk of AATD lung and liver disease.
Circulating wild-type M-AAT protein in plasma reached a mean of 6.9 micromolar at day 15, representing more than 60% of total AAT.
Increases in neutrophil elastase inhibition from baseline were consistent with the production of functional M-AAT.
WVE-006 has been well-tolerated and has a favorable safety profile to date. All adverse events in RestorAATion-2 and the ongoing RestorAATion-1 trial of healthy volunteers are mild to moderate, with no serious adverse events reported.
The RestorAATion-2 trial is ongoing, and Wave expects to share multidose data in 2025.
GSK plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>) has the exclusive global license for WVE-006.
Development and commercialization responsibilities will transfer to GSK after Wave completes the RestorAATion-2 study.
Wave is eligible for up to $525 million in milestones <a target="_blank" href="https://www.benzinga.com/general/biotech/22/12/30058379/wave-life-sciences-shares-move-higher-on-therapeutic-pact-with-gsk-targeting-genetic-disorders" rel="noreferrer noopener">and sales-based royalties</a>.
Price Action: WVE stock is up 74.4% at $14.93 at last check Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/10/41356844/fda-puts-speed-breaker-on-novavaxs-covidflu-combo-shot-trial-on-concerns-related-to-damaged-nerve" target="_blank" rel="noreferrer noopener">FDA Puts Speed Breaker On Novavax&#8217;s COVID/Flu Combo Shot Trial On Concerns Related To Damaged Nerves</a>.</li>
</ul>
Image created using artificial intelligence via Midjourney.

Biotech

Health Care

General

Wave Life Sciences Reveals RNA Editing Breakthrough, Reports First-Ever Clinical Proof-Of-Mechanism In Humans

U.S. stocks were mixed, with the Dow Jones index gaining around 100 points on Wednesday.
Shares of United Airlines Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UAL#NASDAQ">UAL</a>) rose sharply during Tuesday's session following <a href="https://www.benzinga.com/news/earnings/24/10/41345371/united-airlines-q3-earnings-revenue-beat-eps-beat-1-5b-buyback-clear-inflection-point">better-than-expected quarterly earnings.</a>
United Airlines reported third-quarter revenue of $14.843 billion, beating the consensus estimate of $14.783 billion, according to Benzinga Pro. The airline company reported adjusted earnings of $3.33 per share, beating analyst estimates of $3.13 per share.
United Airlines gained 9.3% to $70.04 on Wednesday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>Korro Bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRRO#NASDAQ">KRRO</a>) gained 80% to $71.72.</li>
<li>Wave Life Sciences Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WVE#NASDAQ">WVE</a>) jumped 62.5% to $13.91. Wave Life Sciences achieved first-ever therapeutic RNA editing in humans with results from RestorAATion-2 trial of WVE-006 for Alpha-1 Antitrypsin Deficiency.</li>
<li>Oklo Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OKLO#NYSE">OKLO</a>) gained 21% to $14.20. The DOE approved the company&#8217;s conceptual safety design report for its Aurora fuel fabrication facility. This will advance plans to utilize recovered material for its first commercial powerhouse.</li>
<li>NuScale Power Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMR#NYSE">SMR</a>) rose 18.1% to $16.09.</li>
<li>Altus Power, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMPS#NYSE">AMPS</a>) gained 18% to $3.5645 after the company announced that a formal review of strategic alternatives has been underway by its Board of Directors. Also, the company reaffirmed its FY24 guidance.</li>
<li>Centrus Energy Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LEU#NYSE">LEU</a>) jumped 15.8% to $71.00.</li>
<li>Lithium Americas Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LAC#NYSE">LAC</a>) gained 14.8% to $3.0689 after the company announced it entered into a new investment agreement with General Motors Holdings to establish a joint venture for the purpose of funding, developing, constructing and operating Thacker Pass in Humboldt County, Nevada.</li>
<li>Aspen Aerogels, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASPN#NASDAQ">ASPN</a>) surged 14.1% to $25.61. Aspen Aerogells won conditional commitment for proposed DOE loan of up to $670.6 million.</li>
<li>MP Materials Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MP#NYSE">MP</a>) gained 7.6% to $19.05.</li>
<li>Morgan Stanley (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MS#NYSE">MS</a>) rose 6.9% to $119.92 after the company reported better-than-expected third-quarter financial results.</li>
<li>U.S. Bancorp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USB#NYSE">USB</a>) gained 5.2% to $49.44 following upbeat quarterly earnings.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/10/41329813/jim-cramer-we-need-more-uranium-recommends-this-stock-says-novo-nordisk-doesnt-hold-a-ca">Jim Cramer: &#8216;We Need More Uranium,&#8217; Recommends This Stock; Says Novo Nordisk &#8216;Doesn&#8217;t Hold A Candle&#8217; To Big Pharma Rival</a></li>
</ul>

Intraday Update

AMPS

ASPN

United Airlines Posts Upbeat Earnings, Joins Morgan Stanley, U.S. Bancorp And Other Big Stocks Moving Higher On Wednesday

Single Dose Raises Wild-Type M-AAT Levels To 60% Of Total AAT, With Durable Effects Observed Through 57 Days; Multidose Data Expected In 2025

Wave Life Sciences Achieves First-Ever Therapeutic RNA Editing In Humans With Results From RestorAATion-2 Trial Of WVE-006 For Alpha-1 Antitrypsin Deficiency

RBC Capital analyst Luca Issi maintains WAVE Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WVE#NASDAQ">WVE</a>) with a Sector Perform and raises the price target from $5 to $7.

RBC Capital Maintains Sector Perform on WAVE Life Sciences, Raises Price Target to $7

B. Riley Securities analyst Madison El-Saadi maintains WAVE Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WVE#NASDAQ">WVE</a>) with a Buy and raises the price target from $11 to $19.

B. Riley Securities Maintains Buy on WAVE Life Sciences, Raises Price Target to $19

JP Morgan analyst Eric Joseph reinstates WAVE Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WVE#NASDAQ">WVE</a>) with a Overweight and raises the price target from $10 to $13.

Initiation

JP Morgan Reinstates Overweight on WAVE Life Sciences, Raises Price Target to $13

Wave Life Sciences shares are trading lower after the company announced the pricing of its upsized $200 million offering of 23.1 million shares at $8 per share.

The Federal Reserve rate cuts have sent the market up, but some stocks are rising more than others. That includes small pharmaceutical companies like Wave Life Sciences (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/wve#NASDAQ">WVE</a>), whose shares rose 9% the day after the central bank reduced rates by 50 basis points.
However, rate cuts are not the only reason for excitement around the company. The average of recent Wall Street analyst price targets signals an 85% upside potential in the stock. I&#39;ll analyze the progress Wave Life Sciences has made in its treatment, its financial situation, and what to watch for next.
<h2>Wave May Have an &quot;Industry-Leading&quot; DMD Treatment</h2>
Wave currently has four drugs in development, but I&#39;ll focus on WVE-N531. This drug aims to treat Duchenne Muscular Dystrophy (DMD), a condition that mostly affects young boys. The drug is currently in Phase 2 Food and Drug Administration (FDA) trials.
DMD is characterized by low levels of dystrophin production. One of the main ways to increase dystrophin production is through &quot;exon skipping.&quot; These drugs help the body skip over malfunctioning parts of the genetic code (exons) that cause low dystrophin levels. By skipping over these exons, the body should produce more dystrophin. Wave&#39;s drug specifically aims to skip over exon 53.
In the company&#39;s preclinical trials, the drug achieved exon skipping levels of 53%. The firm says this percentage is &quot;industry-leading.&quot; Although the company does not cite how much dystrophin production increased, exon skipping correlates with it. So, it is possible that dystrophin production could be industry-leading as well.
From a business perspective, one issue with this treatment is that the market is very small. Different people are affected by different exons malfunctioning. Since WVE-N531 is being researched specifically to skip exon 53, it is currently only aimed at treating 8% to 10% of DMD patients. In the United States and Europe, that is only around 2,300 people. Still, this could result in significant revenue.
According to the firm, exon-skipping treatments brought in $1 billion industry-wide in 2023. Those affected by exon 53 make up around a quarter of the total when looking at the five largest exon patient groups. So, it&#39;s conceivable that there may be a current market of around $250 million for the drug. The DMD market is expected to continue growing considerably; however, estimates are wide-ranging, from 10% to 39% per year.
<h2>Wave&#39;s Financials Show Positives and Negatives</h2>
Over the past several years, Wave Life Sciences hasn&#39;t been a good investment at all. The stock has provided a cumulative total return of just 5% in three years. As with many small firms in the pharma industry, Wave currently has no approved medications. However, the company has been able to generate some significant revenue.
Wave has generated at least $12 million in revenue in each of the last six quarters. This revenue mainly comes from &quot;collaborations&quot; with large pharmaceutical companies.&nbsp;Takeda (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/tak#NYSE">TAK</a>)&nbsp;and&nbsp;GSK (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/gsk#NYSE">GSK</a>) have collaborated with Wave. Although Wave isn&#39;t generating&nbsp;much revenue, anything helps when the company is spending $30 million to $40 million a quarter on research and development.
The company currently has $154 million in cash and equivalents on its balance sheet. That may last a little over a year, considering the company has burned through $130 million in cash from operations over the last twelve months. It will need to issue more stock soon, which will dilute shareholders.
<h2>Good News Around WVE-N531 and What to Watch For</h2>
The company&nbsp;recently received good news regarding the drug. The FDA granted the drug the&nbsp;Rare Pediatric Disease Designation. This means that if the drug is approved, the company will receive a Priority Review Voucher (PRV). The PRV allows the company to speed up the review of a future drug by four months. However, PRVs can also be sold to other companies.
Recent data shows that PRVs are now selling for an average of $100 million. Thus, selling the PRV could bring in significant revenue if WVE-N531 is approved. Alternatively, it could use the PRV itself to speed up the review of its own future treatments.
I&#39;ll be watching Waves&#39; upcoming results for WVE-N531, which they plan to release in Q3. The results will include data on changes in dystrophin levels. Seeing the number come in above the 5.7% to 5.9% increase of the already approved treatment Viltepso could add significant validity to the Wave Life Sciences bull case.
The article &quot;<a href="https://www.marketbeat.com/stock-ideas/analysts-predict-85-upside-for-wave-life-sciences-after-rate-cut/">Analysts Predict 85% Upside for Wave Life Sciences After Rate Cut</a>&quot; first appeared on MarketBeat.

Large Cap

Small Cap

Federal Reserve

Analysts Predict 85% Upside for Wave Life Sciences After Rate Cut

Wave Life Sciences Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WVE#NASDAQ">WVE</a>), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, announced today the pricing of its previously announced underwritten public offering of 23,125,001 of its ordinary shares at a price to the public of $8.00 per ordinary share, and, in lieu of ordinary shares to certain investors, pre-funded warrants to purchase up to 1,875,023 ordinary shares at an offering price of $7.9999 per pre-funded warrant, which represents the per share offering price for the ordinary shares less the $0.0001 per share exercise price for each pre-funded warrant.
&nbsp;
Gross proceeds to Wave Life Sciences from the offering are expected to be approximately $200 million, before deducting underwriting discounts and commissions and offering expenses. All of the securities in the offering are being sold by Wave Life Sciences. In addition, Wave Life Sciences has granted the underwriters a 30-day option to purchase up to an additional 3,750,000 of its ordinary shares on the same terms and conditions. The offering is expected to close on or about September 27, 2024, subject to customary closing conditions. 
&nbsp;

Offerings

Reported Earlier, Wave Life Sciences Upsizes Offering To $200M Of 23.1M Shares At $8/Share

Wave Life Sciences shares are trading higher after HC Wainwright maintained a Buy rating on the stock and raised its price target from $15 to $22.

Jones Trading analyst Catherine Novack maintains WAVE Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WVE#NASDAQ">WVE</a>) with a Buy and raises the price target from $12 to $16.

Jones Trading Maintains Buy on WAVE Life Sciences, Raises Price Target to $16

The latest announcement is out from Wave Life Sciences ( ($WVE) ). Wave Life Sciences Ltd. has achieved a breakthrough in therapeutic RNA editing, ...

Wave Life Sciences Advances in RNA Editing Innovation

Wave stock soars 38% on positive data for AATD therapy WVE-006

Takeda declines to exercise option for Wave's WVE-003

Wave stock soars 66% on positive data for RNA editing treatment (update)

Joseph Schwartz, an analyst from Leerink Partners, reiterated the Buy rating on Wave Life Sciences (WVE – Research Report). The associated price ta...

Wave Life Sciences: Buy Rating Affirmed on Promising RNA Editing Platform Data

Wave stock soars 73% on positive data for RNA editing treatment (update)

Wave Life Sciences: Positive WVE-006 Data For AATD Leads To 2025 Catalyst

Analyst Tiago Fauth from Wells Fargo maintained a Buy rating on Wave Life Sciences (WVE – Research Report) and increased the price target to $22.00...

Wave Life Sciences: Increased Probability of Success Drives Buy Rating Amid Platform Advancements

Truist Financial analyst Joon Lee assigned a Buy rating to the stock today. The company's shares closed yesterday at $14.90. Lee covers the Healthc...

Wave Life Sciences (WVE) Gets a Buy from Truist Financial

Mizuho Securities analyst Salim Syed has maintained their bullish stance on WVE stock, giving a Buy rating today. Salim Syed's rating is based on s...

Positive Outlook for Wave Life Sciences Driven by Promising RNA Editing Data and Strategic Opportunities

GLAXF

PRQR

TKPHF

Press Releases

Wave Life Sciences Second Quarter 2024 Financial Results Scheduled for August 8, 2024

Earnings

Wave Life Sciences Reports Second Quarter 2024 Financial Results and Provides Business Update

Wave Life Sciences Receives FDA Rare Pediatric Disease Designation for WVE-N531 for the Treatment of Duchenne Muscular Dystrophy

Wave Life Sciences Announces Positive Interim Data from FORWARD-53 Clinical Trial Evaluating WVE-N531 in Boys with Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping

Financing

Wave Life Sciences Announces Proposed Public Offering of Ordinary Shares and Pre-Funded Warrants

Wave Life Sciences Prices Upsized $200 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

Wave Life Sciences to Present at Chardan 8th Annual Genetic Medicines Conference

Wave Life Sciences Announces Closing of Upsized Public Offering of Ordinary Shares and Pre-Funded Warrants and Full Exercise of Underwriters' Option to Purchase Additional Shares

Wave Life Sciences Announces Upcoming Virtual Research Day on Wednesday, October 30, 2024

Wave Life Sciences Announces First-Ever Therapeutic RNA Editing in Humans Achieved in RestorAATion-2 Trial of WVE-006 in Alpha-1 Antitrypsin Deficiency

Amphastar Pharmaceuticals, Inc. - Common Stock

Amphastar Pharma

Amneal Pharmaceuticals, Inc. - Class A Common Stock

Amneal Pharmaceuticals

ANI Pharmaceuticals

Arvinas

Axsome Therapeutics

Belite Bio, Inc - American Depositary Shares

Belite Bio

Corcept Therapeutics Incorporated - Common Stock

Corcept Therapeutics

Enliven Therapeutics, Inc. - Common Stock

Enliven Therapeutics

Edgewise Therapeutics, Inc. - Common Stock

Edgewise Therapeutics

Structure Therapeutics Inc. - American Depositary Shares

Structure Therapeutics

HUTCHMED (China) Limited - American Depositary Shares

HUTCHMED (China)

Harmony Biosciences Holdings, Inc. - Common Stock

Harmony Biosciences

Harrow

Innoviva

Longboard Pharmaceuticals, Inc. - Common Stock

Longboard Pharmaceuticals

Ligand Pharmaceuticals Incorporated - Common Stock

Ligand Pharmaceuticals

Neumora Therapeutics, Inc. - Common Stock

Neumora Therapeutics

Ocular Therapeutix

Organon

Prestige Consumer Healthcare Inc. Common Stock

Prestige Consumer

Cassava Sciences

Supernus Pharmaceuticals, Inc. - Common Stock

Supernus Pharmaceuticals

Tarsus Pharmaceuticals, Inc. - Common Stock

Tarsus Pharmaceuticals

Tilray Brands

Verona Pharma plc - American Depositary Shares

Verona Pharma

JP Morgan

HC Wainwright & Co.

Raymond James

Wells Fargo

Leerink Partners

이들 7개 중형주는 지난주 최고의 성과를 거두었다. 그것들이 당신의 포트폴리오에 있나요?
1. 오클로(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OKLO#NYSE">OKLO</a>)의 주식은 지난주 99.23% 급등했다. 이는 아마존(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>)의 AWS가 <a href="https://www.benzinga.com//node/41358363" target="_blank" rel="noreferrer noopener">5억 달러 이상을 핵 발전에 투자할 계획을 발표</a>한 후 원자력 관련 주식들의 상승에 따른 것 이다.
2. 웨이브 라이프 사이언스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WVE#NASDAQ">WVE</a>)의 주식은 회사가 RestorAATion-2 시험에서 <a href="https://www.benzinga.com//node/41359843" target="_blank" rel="noreferrer noopener">알파-1 안티트립신 결핍증</a>에 대한 WVE-006의 최초 인류 치료 RNA 편집에 성공했다고 발표한 후 67.35% 급등했다. 여러 애널리스트들이 주가 목표를 <a href="https://www.benzinga.com/quote/wve/analyst-ratings" target="_blank" rel="noreferrer noopener">상향 조정</a>했다.
3. 롱보드 파마슈티컬스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LBPH#NASDAQ">LBPH</a>)의 주식은 회사가 룬드벡(Lundbeck)에 의해 <a href="https://www.benzinga.com//node/41313129" target="_blank" rel="noreferrer noopener">주당 60달러 현금으로 인수될 것</a>이라고 발표한 후 52.21% 상승했다.
4. 울프스피드(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WOLF#NYSE">WOLF</a>)의 주식은 반도체 및 과학 법(<a href="https://www.benzinga.com//node/41339603" target="_blank" rel="noreferrer noopener">CHIPS and Science Act)</a>에 따른 최대 7억 5천만 달러의 직접 자금 지원을 위한 비구속적 예비 계약을 체결한 후 42.44% 급등했다.
5. 클린스파크(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLSK#NASDAQ">CLSK</a>)의 주식은 비트코인(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) 가격이 <a href="https://www.benzinga.com//node/41386011" target="_blank" rel="noreferrer noopener">67,000달러 이상</a> 오른 후 34.10% 상승했다.
6. 텔레폰 앤 데이터 시스템즈(NYS:<a class="items-end ticker-link-wrapper inline-flex" href="https://www.benzinga.com/quote/tds" target="_blank" rel="dofollow noopener" aria-label="Go to Quote Page for TDS">TDS</a>)의 주식은 회사의 자회사인 유나이티드 스테이트 셀룰러(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/USM#NYSE">USM</a>)가 <a href="https://www.benzinga.com//node/41403665" target="_blank" rel="noreferrer noopener">AWS 및 PCS 대역의 일부 주파수 라이선스를 판매</a>한다고 발표한 후 26.03% 상승했다.
7. 아이온큐(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IONQ#NYSE">IONQ</a>)의 주식은 회사가 <a href="https://www.benzinga.com/earnings" target="_blank" rel="noreferrer noopener">3분기 재무 결과를 11월 6일 발표</a>할 것이라고 발표한 후 15.31% 상승했다.
추가 읽기:
<ul>
<li><a href="https://kr.benzinga.com/news/usa/stocks/%EB%8B%88%EC%98%A4-asml-%EB%B0%8F-cvs-%ED%97%AC%EC%8A%A4%EB%8A%94-%EC%A7%80%EB%82%9C%EC%A3%BC-%EC%B5%9C%EC%95%85%EC%9D%98-%EC%84%B1%EA%B3%BC%EB%A5%BC-%EB%B3%B4%EC%9D%B8-10%EA%B0%9C-%EB%8C%80%ED%98%95/" target="_blank" rel="noopener">니오, ASML 및 CVS 헬스는 지난주 최악의 성과를 보인 10개 대형주 중 일부 (10월 14일-18일)</a></li>
<li><a href="https://kr.benzinga.com/news/usa/stocks/%EC%BD%94%EC%9D%B8%EB%B2%A0%EC%9D%B4%EC%8A%A4%EC%99%80-%EC%9C%A0%EB%82%98%EC%9D%B4%ED%8B%B0%EB%93%9C-%ED%95%AD%EA%B3%B5%EC%9D%80-%EC%A7%80%EB%82%9C%EC%A3%BC-%EC%B5%9C%EA%B3%A0-%EC%84%B1%EA%B3%BC/" target="_blank" rel="noopener">코인베이스와 유나이티드 항공은 지난주 최고 성과를 보여준 11개 대형주 중 일부 (10월 14일-18일)</a></li>
</ul>
사진 출처: Oklo
다른 트레이더들보다 30분 일찍 독점 시장 움직임 뉴스를 받아보세요. 
Benzinga Pro의 14일 무료 체험을 통해 독점 뉴스 기사를 이용할 수 있어 수백만 명의 다른 트레이더보다 먼저 실행 가능한 거래 뉴스를 얻을 수 있습니다. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Comments

WAVE Life Sciences

뉴스

에 대한 최신 뉴스 WAVE Life Sciences (NASDAQ:WVE) 주식

일요일, 10월 20, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌